Clinical Data — Investor Presentation (March 2006)
30 slides from Clinical Data's investor presentation, Mar 2, 2006
Slide 1: Corporate Overview
Corporate Overview February 28, 2006 Clinical Data, Inc. ®
Slide 2: Forward-Looking Statements
Forward-Looking Statements SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 The following presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for “forward-looking statements” provided by the P
Slide 3: Mission - Therapeutic Diagnostics
Mission - Therapeutic Diagnostics TM Leverage advances in pharmacogenomics (PGx) and genetic biomarker development to provide novel, proprietary diagnostics leading to more efficacious, safer, and less-costly, “targeted” therapies. The right drug for the right patient in the right dosage
Slide 4: Investment Thesis
Investment Thesis Clinical genomics can substantially reduce therapeutic cost while improving patient outcomes Clinical genomics products are: Proprietary High Value Low Regulatory Burden Medically Sound Clinical Data is an emerging leader in commercializing pharmacogenomics to guide drug therapy
Slide 5: Management Team
Management Team Israel Stein, M.D., CEO & President Mark Shooman, Chief Financial Officer Drew Fromkin, President, PGxHEALTH Carol Reed, M.D., Chief Medical Officer Caesar Belbel, Chief Legal Officer Garth Gardner, President, Vital Diagnostics
Slide 6: Ownership
Ownership 13% Institutions 3% Management/Directors 8% Dr. Stein 39% RJ Kirk Percentage Ownership Owner
Slide 7: Clinical Data: From Targeted Science to Better Healthcare
CLINICAL From Targeted Science to Better Healtheare™ CLINICAL # DATA Frm Tid Sir Ber Hod PGxtHEALTH* Introducing Therapeusic Diagnosis” CO;GENICS” Comprehensive Pharmacogenomics "ind Mokcar Serer VITAL?{DIAGNOSTICS” ‘Making Diagnosis Acesible”
Slide 8: Highlights
Highlights 450 employees worldwide Annualized Revenues of $80+ mln Market Cap: ~$200 million NASDAQ National Market CLDA ISO 9001, EN13485, CE, FDA, GLP, CLIA
Slide 9: 2005 Growth Story
2005 Growth Story Business Week, May 2005 #29 of 100 “Hot Growth Companies” Boston Globe 100, May 2005 #9 overall #1 in growth Business 2.0, June 2005 #3 Fastest Growing Tech. Companies Fortune September 2005 #10 Overall
Slide 10: PGxHealth
PGx?HEALTH" @ ADIVISION OF CLINICAL DATA Introducing Therapeutic Diagnostic» CLINICAL # DATA rm Td Set Boe Hote”
Slide 11: PGxHealth
PGxHealth Individualized drug therapies Match a patient with effective and safe medications based on genetic diagnostic tests Personalized disease prevention strategies Develop genetic tests that estimate risk of developing a particular disease, combined with individualized therapies
Slide 12: Reactive vs Predictive
Reactive vs Predictive Diagnosis Drug 2 Drug 3 Drug 4 Drug 1 Time/Cost Reactive Care Diagnosis PGx Drug 1 Time/Cost Predictive Care
Slide 13: Global-U.S. Market / CNS
Global-U.S. Market / CNS Psychotherapeutic Drugs Revenues at U.S. Manufacturers' Sales Levels, 2000-2007
Slide 14: Vilazodone: A Potential Blockbuster
Vilazodone: A Potential Blockbuster Pairing a Novel Antidepressant and Diagnostic ~ 17 million Americans suffer from depressive illness. $9.75+ billion was spent in the U.S. on antidepressants in 2004 First-line treatment is ineffective in 50% of depressed patients Variability among patients’ respon
Slide 15: Vilazodone – A Business Model
Vilazodone – A Business Model Reposition a stalled compound by developing efficacy biomarkers Develop predictive tests concurrently with the drug Identify biomarkers that may be used in proving efficacy for a similar class of drugs in future studies
Slide 16: PGx – The Next Revolution
PGx TM – The Next Revolution GENERIC DRUGS Enabled by legislation, mid-80’s PHARMACY BENEFITS MANAGEMENT Evolved in mid-90’s as part of ‘managed care’, Utilization Management PHARMACOGENOMICS – Therapeutic Diagnostics Infancy – Targeted Therapeutic Care Reduce adverse events Improve patient outcomes
Slide 17: Clinical Data PGx Tests - 2006
Clinical Data PGx Tests - 2006 Maintain Through Prometheus Develop and Launch Initiate Phase III Validate - Launch Expand Sales Oncology Cardiology CNS CNS Cardiology Therapeutic Area Childhood Leukemia – Drug Toxicity TPMT Test Coagulation Warfarin Depression – SSRI Vilazodone Antipsychosis CARING
Slide 18: Near Term Opportunities with Payers/Employers
Near Term Opportunities with Payers/Employers Distribution avenue for tests via payers and providers Build into best practice protocols and managed care plan designs to reduce medical costs Fund and accelerate new biomarker discovery with partners Co-development of content and decision support tools
Slide 19: Strategic Development of PGx Tests
Strategic Development of PGx Tests Advance quality measures Decrease overall drug costs Decrease total cost of care Pay-for-performance hot spots Competing therapies, reinvigoration of therapies Emphasis on neuro-psychiatric, cardiology, oncology
Slide 20: Cogenics
CO:GENICS” © ADWVISION OF CLINICAL DATA Comprehensive Pharmacogenomics and Molecular Servicesm CLINICAL # DATA rm Td Set Boe Hote”
Slide 21: Molecular Services/Laboratory Business
Molecular Services/Laboratory Business Leading provider of CLIA regulated, GLP & research DNA/RNA analysis services. Locations in: - New Haven, CT - Morrisville, NC - Houston, TX - Takeley, Cambridge UK. Strong offerings to key markets: pharmaceutical, biotech, agricultural, government, and academia
Slide 22: Comprehensive Molecular and Pharmacogenomics Services Business
Sequencing Genotyping Molecular Sciences Gene Expression/Pathway Analysis Extraction and BioBanking Supports development of BioMarkers and Molecular Diagnostics Comprehensive Molecular and Pharmacogenomics Services Business Research Clinical Preclinical Post Launch Clinical PGx/Dx Molecular Services
Slide 23: Vital Diagnostics
VITAL:DIAGNOSTICS” © ADIVISION OF CLINICAL DATA Making Diagnostics Accessible” CLINICAL # DATA rm Td Set Boe Hote”
Slide 24: Vital Diagnostics Division
Vital Diagnostics Division - Clinical Data S&S, Inc. Smithfield RI and Brea CA Equipment distribution, reagent manufacturing & consulting - Vital Scientific NV Spankeren, The Netherlands Instrumentation Development and Production - Vital Diagnostics Pty. Ltd. Sydney, Australia Diagnostics distributi
Slide 25: Clinical Data
CLINICAL DATA rm Td Set Boe Hote”
Slide 26: Financial Summary
Financial Summary Income Statement (000’s) For Three Months Ended December 31, For the Nine MonthsEnded December 31, REVENUES Products $13,780 $12,653 $ 36,426 $38,599 Services 6,121 1,707 9,136 5,123 Total 19,901 14,360 45,562 43,722 COST OF REVENUES Products 8,960 8,250 23,481 25,192 Services 2,95
Slide 27: Financial Summary - Balance Sheet Highlights
Financial Summary Balance Sheet Highlights 62,168 23,809 20,264 5,346 Stockholders Equity 13,206 1,976 2,048 Debt 120,572 39,146 38,318 11,198 Total Assets 30,654 6,350 6,350 - Goodwill 48,409 25,408 26,349 8,909 Current Assets 13,607 4,171 1,800 Cash 12/31/2005 3/31/2005 3/31/2004 3/31/2003
Slide 28: Key Drivers in 2006
Key Drivers in 2006 Vilazodone Phase III clinical trial and biomarker development Grow PGxHEALTH organically and through in-licensing Establish biomarker discovery partnerships around near-term test development Ongoing development of existing biomarkers Grow molecular and pharmacogenomics services b
Slide 29: Clinical Data Summary
Clinical Data Summary Emerge as a leader in clinical PGx by offering Therapeutic Diagnostics to improve patient outcomes and reduce the cost of care Develop genomic tests that are high margin and value priced based on their unique, proprietary nature and impact on cost reductions in healthcare Maint
Slide 30: Corporate Overview
Corporate Overview February 28, 2006 Clinical Data, Inc. ®